Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
2020· article· en· The Lancet Oncology· Medicine
affsans résumé
2 492
citations